Clinical Trial Search

Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Frequency of Eating in Response to Cravings (Primary Mechanistic Outcome) — -20.39; -25.27 % of EMAs with craving related eating

Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539

Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events

Primary: Disposition Index — 0.023; 0.149 index

Primary: Neuropathic Pain — 482; 461; 560 Participants

Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index

Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL

Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change

Primary: Between Group Difference in HbA1c When Comparing CSII to MDI — -1.1; -0.4 Change in % HbA1c

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin

Primary: HBA1c at One Year — 8.5; 7.7; 7.9; 7.9 percentage of HbA1c — p=0.027

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR — 80.4; 71.2 index of beta-cell function

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Radiographic Bone Level — 2.69; 2.54 mm

Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL